RxDoctor Payments Data

Bruce Skolnick, MD

Cardiovascular Disease · Clifton, NJNPI 1700831831

Payments from drug & device makers

$3,771in general payments, 2019–2025

Across 137 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$717
  • Novartis$457
  • Edwards Lifesciences$395
  • Medtronic$312
  • Abiomed$310
  • Biotronik Inc.$257
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,771100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,771 in reported general payments places this provider in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$328,548
Medicare patients
1,072
Services billed
3,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$236,809
XareltoRivaroxaban82$86,162
EntrestoSacubitril/Valsartan33$48,781
BrilintaTicagrelor27$29,023
Repatha SureclickEvolocumab34$28,716
FarxigaDapagliflozin Propanediol13$14,885
Praluent PenAlirocumab14$12,931
MultaqDronedarone Hcl14$11,071
Metoprolol Succinate482$7,531
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,596
Atorvastatin Calcium381$4,333
CozaarLosartan Potassium15$4,064
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$3,390
Rosuvastatin Calcium213$3,267
Nebivolol Hcl61$2,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$236,809203 claims
Johnson & JohnsonXarelto$72$86,16282 claims
NovartisEntresto$457$48,78133 claims
AstraZenecaBrilinta, Farxiga$118$43,90740 claims
Sanofi-aventis U.S. LLCMultaq$27$11,07114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →